clinical gastroenterology and hepatology : the official clinical practice journal of the american gastroenterological association2019Vol. 17pp. -
267
bg2019clinicalrapid
Abstract
In a post-hoc analysis of data from phase 3 clinical trials, vedolizumab significantly improved patient-reported symptoms of UC and CD as early as week 2 of treatment, continuing through the first 6 weeks-especially when given as first-line biologic therapy. ClinicalTrials.gov no: NCT00783718, NCT00 …